IfPA’s Patient Access Policy Blog

New Cystic Fibrosis Group Weighs in on Obamacare Revamp

As Congress continues to debate the future of the Affordable Care Act, a new advocacy group has a message for key legislators: protect cystic fibrosis

Read More

Does ICER Model Work for Rheumatoid Arthritis Treatments?

The Institute for Clinical and Economic Review’s newest cost-effectiveness report underscores just how far economic modeling sometimes diverges from patients’ reality, explained the Institute for

Read More

Fewer Treatment Choices and Higher Costs Plague Diabetes Patients

Access to medication has become an all-too-common challenge for patients with one of the country’s most common diseases: diabetes. Several health plans announced in late

Read More

Why Impact & Cost of Chronic Migraine Comorbidities Justify “Whole-Person” Care

Chronic migraine is seldom a lone condition, explains a new white paper from the Headache & Migraine Policy Forum.  And when chronic migraine patients suffer

Read More

Trials Data Strengthens Patients’ Demands for Breakthrough Cholesterol Meds

New data on PCSK9 inhibitors is in – and it may bolster patients’ demands for the breakthrough cholesterol drugs in the face of health plan

Read More

Rising Cancer Survivorship Brings New Policy Challenges

More patients are living longer with cancer – and that’s good news.  But some face policies, health care providers and workplaces that are unprepared to

Read More

Medical Groups Propose 21 Principles for Prior Authorization Reform

The American Medical Association and 16 patient, physician, hospital and pharmacy groups have issued a resounding message to health plans: it’s time to reform prior

Read More

Government Nutrition Advice Gives Mixed Message to Pregnant Women

Eating fish offers pregnant women nutritional benefits for both themselves and their developing babies.  But, looking at newly published advice from the Food and Drug

Read More

The Obama Administration’s Final Say on Opioids

This month’s change in presidential administrations prompted some final words – and policy – from federal agencies on the subject of opioids. First, the Centers

Read More

Patient Safety Questions Linger after FDA Issues Interchangeability Guidance

New guidance from the Food and Drug Administration directs companies on how to demonstrate a biosimilar’s interchangeability with its reference product.  The draft outlines the

Read More
Back to Top